Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Below averageWe are a leading global oncology company discovering and developing innovative treatments that are more accessible to cancer patients worldwide. In 2025, we generated total global revenue of approximately $5.3 billion, increasing revenue by approximately 40.2% from the prior year, while achieving net income of $286.9 million, net cash provided by operating activities of $1.1 billion and positive free cash flow of $941.7 million.
In the company’s own words · 10-K filed Feb 26, 2026 · SEC EDGAR
Business segments
Jun 2026 · $1.73BThe company’s own SEC segment disclosure.
- BRUKINSA$1.25B72%
- TEVIMBRA$228.5M13%
- XGEVA$104.5M6%
- Other$37.8M2%
- BLINCYTO$36.5M2%
- Other$25.3M1%
- Other (5)$50.1M3%
Its largest product in Jun 2026 was BRUKINSA at $1.25B, 72% of the disclosed total, well ahead of TEVIMBRA at 13%.